Published in J Virol on November 01, 1995
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol (2002) 4.47
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol (1998) 3.21
Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol (1995) 2.88
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature (2015) 2.87
Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol (1996) 2.86
Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J (1996) 2.84
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82
HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev (1998) 2.82
Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog (2008) 2.72
Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A (2007) 2.64
The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J Virol (2009) 2.57
Comprehensive analysis of ebola virus GP1 in viral entry. J Virol (2005) 2.56
Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines. J Virol (2003) 2.46
Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol (2001) 2.35
Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol (1996) 2.33
HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog (2007) 2.13
Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.08
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J Virol (1998) 1.97
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. J Virol (2000) 1.85
Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol (1996) 1.80
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol (2004) 1.80
Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J Virol (1999) 1.79
The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J Virol (2000) 1.79
APOBEC3G targets specific virus species. J Virol (2004) 1.78
DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol (2007) 1.77
Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6(gag). J Virol (2000) 1.76
Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirology (2010) 1.76
In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol (1998) 1.73
Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol (1998) 1.70
The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology (2005) 1.67
HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog (2006) 1.67
Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol (2004) 1.66
Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol (1997) 1.65
HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood (2009) 1.63
A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol (2006) 1.62
Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol (2000) 1.61
Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol (2009) 1.61
Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J Virol (1997) 1.60
A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J Virol (1999) 1.60
The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A (2006) 1.58
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58
The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J Virol (2008) 1.57
Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J Virol (1998) 1.54
Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells. J Virol (2000) 1.54
The cytolethal distending toxin from the chancroid bacterium Haemophilus ducreyi induces cell-cycle arrest in the G2 phase. J Clin Invest (1999) 1.52
Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci U S A (1999) 1.52
Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. J Virol (1997) 1.52
Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol (2002) 1.51
Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways. J Cell Biol (1998) 1.50
HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J Biol Chem (2010) 1.49
Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol (2006) 1.49
Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med (1998) 1.49
Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol (1998) 1.48
Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology (2007) 1.48
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol (2006) 1.47
Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol (2007) 1.45
Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathog (2009) 1.45
HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med (2001) 1.45
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol (2007) 1.44
The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med (1999) 1.43
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol (2001) 1.40
Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J Virol (1999) 1.39
Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J Virol (1997) 1.37
Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol (1999) 1.37
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36
Macrophage signaling in HIV-1 infection. Retrovirology (2010) 1.35
HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc Natl Acad Sci U S A (1998) 1.35
Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J Virol (2005) 1.34
Analysis of hemagglutinin-mediated entry tropism of H5N1 avian influenza. Virol J (2009) 1.33
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother (2005) 1.31
Reovirus-induced G(2)/M cell cycle arrest requires sigma1s and occurs in the absence of apoptosis. J Virol (2000) 1.31
Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol (2003) 1.31
Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol (2000) 1.30
The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS. J Exp Med (1998) 1.30
Influenza A virus replication induces cell cycle arrest in G0/G1 phase. J Virol (2010) 1.30
Development of multigene and regulated lentivirus vectors. J Virol (2000) 1.30
Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus. J Virol (2005) 1.30
Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells. Mol Cell Biol (1998) 1.30
HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol (2008) 1.29
Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol (2001) 1.27
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis (2016) 1.26
5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol (2009) 1.25
Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J Virol (1996) 1.24
Identification of a G(2) arrest domain in the E1 wedge E4 protein of human papillomavirus type 16. J Virol (2002) 1.21
Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses (2010) 1.21
Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol (2001) 1.21
The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T cells than the vesicular stomatitis virus glycoprotein G envelope. J Virol (2009) 1.20
RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol (2010) 1.18
Activation of transcription factors NF-kappaB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression. J Virol (2000) 1.17
Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol (2010) 1.17
TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol (2011) 1.16
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res (1990) 20.53
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Principles of CDK regulation. Nature (1995) 13.09
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol (1993) 5.30
Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med (1992) 5.29
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol (1991) 4.74
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr (1990) 4.35
Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites. EMBO J (1991) 4.24
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol (1995) 4.19
The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Mol Cell Biol (1992) 4.17
Premature p34cdc2 activation required for apoptosis. Science (1994) 4.15
Progression to AIDS in the absence of a gene for vpr or vpx. J Virol (1995) 3.96
Mutational analysis of the human immunodeficiency virus vpr open reading frame. J Virol (1989) 3.48
Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci U S A (1992) 3.38
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Viruses and apoptosis. Curr Opin Genet Dev (1995) 3.26
Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: evidence for a double block to p34cdc2 kinase activation in vertebrates. EMBO J (1991) 3.23
Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology (1994) 3.16
Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell (1993) 2.90
Cdc2 regulatory factors. Curr Opin Cell Biol (1994) 2.78
A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry (1991) 2.60
Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci U S A (1994) 2.29
Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells. J Virol (1989) 2.28
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells. Arch Virol (1992) 1.81
Control of the higher eukaryote cell cycle by p34cdc2 homologues. Biochim Biophys Acta (1989) 1.74
Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection. J Virol (1995) 1.70
Generation and characterization of the human immunodeficiency virus type 1 mutants. Arch Virol (1991) 1.62
The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol (1986) 1.43
Rescue from granzyme B-induced apoptosis by Wee1 kinase. J Exp Med (1995) 1.19
Vertebrate p34cdc2 phosphorylation site mutants: effects upon cell cycle progression in the fission yeast Schizosaccharomyces pombe. J Cell Sci (1992) 1.16
Susceptibility to cytotoxic T lymphocyte-induced apoptosis is a function of the proliferative status of the target. J Exp Med (1994) 1.12
Cell cycle arrest by Colcemid differs in human normal and tumor cells. Cancer Res (1994) 1.00
Cell cycle control of apoptosis in human leukemic T cells. J Immunol (1995) 1.00
Granzymes and apoptosis: targeting the cell cycle. Curr Top Microbiol Immunol (1995) 0.96
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature (2000) 10.16
Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. Cell (1986) 8.87
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 6.52
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66
Crystal structure of Arp2/3 complex. Science (2001) 5.51
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (1993) 5.31
Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol (1993) 5.30
Crystal structure of cyclin-dependent kinase 2. Nature (1993) 5.21
Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol (1990) 5.01
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol (1991) 4.31
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
Domain swapping: entangling alliances between proteins. Proc Natl Acad Sci U S A (1994) 4.20
Inhibitory phosphorylation of the APC regulator Hct1 is controlled by the kinase Cdc28 and the phosphatase Cdc14. Curr Biol (1999) 3.96
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 3.53
Insulin-like growth factor II receptor as a multifunctional binding protein. Nature (1987) 3.52
Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis (1996) 3.40
Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci U S A (1992) 3.38
Brassinosteroid-insensitive dwarf mutants of Arabidopsis accumulate brassinosteroids. Plant Physiol (1999) 3.37
A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell (1994) 3.35
Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol (1997) 3.33
Use of the objective structured clinical examination for assessment of vocational trainees for general practice. J R Coll Gen Pract (1987) 3.28
A late mitotic regulatory network controlling cyclin destruction in Saccharomyces cerevisiae. Mol Biol Cell (1998) 3.18
Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature (1995) 3.05
The Polo-related kinase Cdc5 activates and is destroyed by the mitotic cyclin destruction machinery in S. cerevisiae. Curr Biol (1998) 2.92
Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol (1995) 2.88
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev (1995) 2.72
Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell (1992) 2.68
Bradycardia after amphotericin, irradiation, and anthracycline. Lancet (1992) 2.68
Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol (1997) 2.59
Crystal structure of the tetramerization domain of the Shaker potassium channel. Nature (1998) 2.56
A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol (2000) 2.47
Consensus meeting: monosodium glutamate - an update. Eur J Clin Nutr (2006) 2.44
LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol Cell Biol (1991) 2.41
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 2.38
Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol (2000) 2.36
Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol (1999) 2.35
Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol (1998) 2.33
Type C botulism in dairy cattle from feed contaminated with a dead cat. J Vet Diagn Invest (2000) 2.32
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology (2009) 2.32
Association of p60c-src with endosomal membranes in mammalian fibroblasts. J Cell Biol (1992) 2.30
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Improved procedure for the isolation of a double-strand-specific ribonuclease and its application to structural analysis of various 5S rRNAs and tRNAs. Eur J Biochem (1986) 2.25
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol (1996) 2.21
Pds1 and Esp1 control both anaphase and mitotic exit in normal cells and after DNA damage. Genes Dev (1999) 2.14
A model of saccade generation based on parallel processing and competitive inhibition. Behav Brain Sci (1999) 2.12
Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol (1973) 2.12
Medical and surgical peer review. Am J Surg (1994) 2.11
Pitx2 determines left-right asymmetry of internal organs in vertebrates. Nature (1998) 2.10
Low-birth-weight symposium: summary of proceedings. CMAJ (1993) 2.09
Crystal structure of a synthetic triple-stranded alpha-helical bundle. Science (1993) 2.09
Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J (1994) 2.08
Changes in drug treatment after discharge from hospital in geriatric patients. BMJ (1992) 2.05
Extradural vein puncture--an avoidable complication. Anaesthesia (1991) 2.02
Public health. The cholera crisis in Africa. Science (2009) 2.02
Next-generation sequencing: the solution for high-resolution, unambiguous human leukocyte antigen typing. Hum Immunol (2010) 1.95
Cell cycle control by a complex of the cyclin HCS26 (PCL1) and the kinase PHO85. Science (1994) 1.94
Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell (1995) 1.92
Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol (2004) 1.90
Refined structure of dimeric diphtheria toxin at 2.0 A resolution. Protein Sci (1994) 1.88
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol (2000) 1.81
Nitrate, nitrite and N-nitroso compounds. Eur J Pharmacol (1994) 1.81
Insulin action is blocked by a monoclonal antibody that inhibits the insulin receptor kinase. Proc Natl Acad Sci U S A (1986) 1.80
Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant (2012) 1.80
Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2006) 1.79
Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology (1998) 1.76
Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. J Virol (1984) 1.75
Acute insulin action requires insulin receptor kinase activity: introduction of an inhibitory monoclonal antibody into mammalian cells blocks the rapid effects of insulin. Proc Natl Acad Sci U S A (1987) 1.73
Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol (1994) 1.71
The future of child benefits in the United Kingdom. Arch Dis Child (1988) 1.71
The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry (1999) 1.70
A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science (1996) 1.68
Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J (1994) 1.67
Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med (1990) 1.65
Domain movement in gelsolin: a calcium-activated switch. Science (1999) 1.65
Cdc37 is required for association of the protein kinase Cdc28 with G1 and mitotic cyclins. Proc Natl Acad Sci U S A (1995) 1.62
Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res Hum Retroviruses (1998) 1.62
The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by human immunodeficiency virus type 1 Nef. J Virol (1994) 1.60
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart (2001) 1.59
Cdc14 activates cdc15 to promote mitotic exit in budding yeast. Curr Biol (2000) 1.58
Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int (2001) 1.57
Zn2+-binding and molecular determinants of tetramerization in voltage-gated K+ channels. Nat Struct Biol (1999) 1.57